194 related articles for article (PubMed ID: 28386557)
1. Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.
El Gamal H; Eid AH; Munusamy S
Biomed Res Int; 2017; 2017():5903105. PubMed ID: 28386557
[TBL] [Abstract][Full Text] [Related]
2. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
3. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
4. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
5. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy.
Lu Q; Ji XJ; Zhou YX; Yao XQ; Liu YQ; Zhang F; Yin XX
Pharmacol Res; 2015 Sep; 99():237-47. PubMed ID: 26151815
[TBL] [Abstract][Full Text] [Related]
6. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
[TBL] [Abstract][Full Text] [Related]
7. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
8. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
Tsugawa T; Shinohara R; Nagasaka A; Nakano I; Takeda F; Nagata M; Oda N; Sawai Y; Hayakawa N; Suzuki A; Itoh M
J Endocrinol; 2004 Jun; 181(3):429-35. PubMed ID: 15171691
[TBL] [Abstract][Full Text] [Related]
9. The protective effect of shikonin on renal tubular epithelial cell injury induced by high glucose.
Tong Y; Chuan J; Bai L; Shi J; Zhong L; Duan X; Zhu Y
Biomed Pharmacother; 2018 Feb; 98():701-708. PubMed ID: 29304496
[TBL] [Abstract][Full Text] [Related]
10. Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity.
He JY; Hong Q; Chen BX; Cui SY; Liu R; Cai GY; Guo J; Chen XM
Acta Pharmacol Sin; 2022 Feb; 43(2):342-353. PubMed ID: 34811512
[TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
12. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
ElGamal H; Munusamy S
Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
[TBL] [Abstract][Full Text] [Related]
13. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
[TBL] [Abstract][Full Text] [Related]
14. Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells.
Chen F; Sun Z; Zhu X; Ma Y
Biomed Pharmacother; 2018 Oct; 106():1175-1181. PubMed ID: 30119185
[TBL] [Abstract][Full Text] [Related]
15. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
17. Effects of aldose reductase inhibition with epalrestat on diabetes-induced changes in rat isolated atria.
Booth RJ; Hodgson WC
Clin Exp Pharmacol Physiol; 1993 Apr; 20(4):207-13. PubMed ID: 8485921
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.
Drel VR; Pacher P; Stevens MJ; Obrosova IG
Free Radic Biol Med; 2006 Apr; 40(8):1454-65. PubMed ID: 16631535
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
Sampath C; Sang S; Ahmedna M
Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition effect of epalrestat on rat lens osmotic expansion].
Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
